GTC
PRAX icon

Ghost Tree Capital’s Praxis Precision Medicines PRAX Stock Holding History

Ghost Tree Capital’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,667
Closed -$4.62M – 66
2021
Q3 		$4.62M Buy
+16,667
New +$4.52M 1.35% 28

Other funds holding PRAX

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ghost Tree Capital's PRAX Position: Q4 2021 in Review

Ghost Tree Capital sold out of Praxis Precision Medicines (PRAX) in Q4 2021, closing a stake of 16,667 shares — an estimated $4.62M sold.

Ghost Tree Capital first reported a position in PRAX in Q3 2021 and held it in 1 quarter. The position peaked at $4.62M in Q3 2021. 100 funds tracked by Wall St. Rank hold PRAX as of Q4 2021.

  • Ghost Tree Capital reported no remaining Praxis Precision Medicines position as of Q4 2021 after selling out during the quarter.
  • Ghost Tree Capital sold 16,667 Praxis Precision Medicines shares in Q4 2021, an estimated $4.62M.
  • Ghost Tree Capital first reported a position in Praxis Precision Medicines in Q3 2021 and held it in 1 quarter.
  • Ghost Tree Capital's Praxis Precision Medicines position peaked at $4.62M in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2021.

Based on Ghost Tree Capital's 13F filing for Q4 2021, filed 16 Feb 2022.